Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 3/20 | 0.69 |
| ▸ | GAK | O14976 | 1/20 | 0.69 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.69 |
| ▸ | ULK1 | O75385 | 1/20 | 0.69 |
| ▸ | STK10 | O94804 | 1/20 | 0.69 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.69 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.69 |
| ▸ | LATS1 | O95835 | 1/20 | 0.69 |
| ▸ | PAK4 | O96013 | 1/20 | 0.69 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.69 |
| ▸ | LCK | P06239 | 1/20 | 0.69 |
| ▸ | CDK1 | P06493 | 1/20 | 0.69 |
| ▸ | APRT | P07741 | 1/20 | 0.69 |
| ▸ | RET | P07949 | 1/20 | 0.69 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.69 |
| ▸ | PHKG2 | P15735 | 1/20 | 0.69 |
| ▸ | NQO2 | P16083 | 1/20 | 0.69 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.69 |
| ▸ | FECH | P22830 | 1/20 | 0.69 |
| ▸ | CDK2 | P24941 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3185606 | 0.93 | IRAK4 (0.69) | IRAK4GAKRIPK2ULK1STK10 | |
| SCHEMBL22097637 | 0.92 | IRAK4 (0.69) | IRAK4GAKRIPK2ULK1STK10 | |
| SCHEMBL5762977 | 0.90 | IRAK4 (0.76) | IRAK4GAKRIPK2ULK1STK10 | |
| SCHEMBL3836778 | 0.86 | IRAK4 (0.73) | IRAK4GAKRIPK2ULK1STK10 | |
| SCHEMBL3175049 | 0.86 | IRAK4 (0.64) | IRAK4GAKRIPK2ULK1STK10 | |
| SCHEMBL31060494 | 0.85 | IRAK4 (0.72) | IRAK4GAKRIPK2ULK1STK10 | |
| SCHEMBL29678517 | 0.85 | IRAK4 (0.72) | IRAK4GAKRIPK2ULK1STK10 | |
| SCHEMBL859537 | 0.85 | IRAK4 (0.72) | IRAK4GAKRIPK2ULK1STK10 | |
| SCHEMBL5857006 | 0.85 | IRAK4 (0.72) | IRAK4GAKRIPK2ULK1STK10 | |
| SCHEMBL3836214 | 0.85 | IRAK4 (0.72) | IRAK4GAKRIPK2ULK1STK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11738017-B2 | Method of inhibiting constitutively active phosphorylated FLT3 kinase | AROG PHARMACEUTICALS, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| US-20200375976-A1 | Method of Inhibiting Constitutively Active Phosphorylated FLT3 Kinase | AROG PHARMACEUTICALS, INC. | 2020-12-03 | — | — | US | disclosed |
| US-10251877-B2 | Method of inhibiting mutant C-KIT | AROG PHARMACEUTICALS, INC. (US) | 2019-04-09 | — | — | US | disclosed |
| US-20180125839-A1 | METHOD OF INHIBITING MUTANT C-KIT | AROG PHARMACEUTICALS, LLC | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180125839-A1 | METHOD OF INHIBITING MUTANT C-KIT | KIT, ABL1, PRKCH | IRAK4 1405/4885GAK 404/4885RIPK2 1642/4885 |
| US-20200375976-A1 | Method of Inhibiting Constitutively Active Phosphorylated FLT3 Kinase | FLT3, ABL1, MKI67 | IRAK4 608/4885GAK 409/4885RIPK2 895/4885 |
| US-10251877-B2 | Method of inhibiting mutant C-KIT | KIT, ABL1, PRKCH | IRAK4 1405/4885GAK 404/4885RIPK2 1642/4885 |
| US-11738017-B2 | Method of inhibiting constitutively active phosphorylated FLT3 kinase | FLT3, ABL1, MKI67 | IRAK4 608/4885GAK 409/4885RIPK2 895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.